-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plogosertib in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Myelodysplastic Syndrome Drug Details: Plogosertib is under development for the...
-
Product Insights
Net Present Value Model: Alpine Immune Sciences Inc’s Povetacicept
Empower your strategies with our Net Present Value Model: Alpine Immune Sciences Inc's Povetacicept report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Alps Alpine Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Alps Alpine Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Transitional Cell Carcinoma (Urothelial...
-
Thematic Analysis
Quantum Computing – Thematic Intelligence
Quantum Computing Theme Analysis Report Overview Quantum computers use the properties of quantum physics to store data and perform computations. There are many technologies with the potential to build their foundational quantum bits (qubits). However, it may well be over a decade before companies can deliver the enmeshed systems of high-fidelity qubits needed to usher in the quantum era. The fiendishly difficult engineering problems, excess hype, and pre-revenue phase for many quantum companies mean a protracted quantum winter is in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Lupus Nephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Lupus Nephritis Drug Details: Povetacicept is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Membranous Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Membranous Glomerulonephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Membranous Glomerulonephritis Drug Details: Povetacicept is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in IgA Nephropathy (Berger's Disease) Drug Details: Povetacicept...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Povetacicept in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Povetacicept in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Povetacicept in Systemic Lupus Erythematosus Drug Details: Povetacicept is under...